The US Food and Drug Administration (FDA) has approved the oral formulation of the GLP-1 weight-loss drug Wegovy, making it the first oral GLP-1 therapy cleared for obesity treatment – ahead of rival Eli Lilly’s orforglipron, which is still under FDA review.
The approval marks another milestone for the fast-growing class of weight-loss medicines, with Novo Nordisk indicating the Wegovy tablets are expected to reach the market within weeks. The introduction of an oral option is widely seen as a potential inflection point for obesity treatment, with experts noting it could broaden access and support wider uptake as the category continues to expand.
Regulatory approval & indication
The FDA has authorised once-daily Wegovy tablets for adults with obesity or overweight with weight-related comorbidities to aid sustained weight reduction alongside lifestyle changes. The approval positions the pill as a potential alternative to injectable GLP-1 therapies and is expected to become available in the US in early January 2026.
In addition to weight-loss benefits, Wegovy is indicated to reduce the risk of major cardiovascular events in obese or overweight adults with established cardiovascular disease.
The oral Wegovy pill contains semaglutide, a glucagon-like peptide-1 receptor agonist that mimics a natural hormone to help regulate appetite and promote feelings of fullness. Semaglutide is already established in injectable forms for weight management and diabetes, and this marks its first approval in a high-dose oral format specifically for obesity management.
‘The launch of Wegovy in 2021 changed how obesity was viewed and treated in the US. Now, with Wegovy pill, we are offering a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in phase 3 trials. We are confident that the expansion of Wegovy to a pill will help patients who may have not sought or accepted treatment before,’ said Dave Moore, executive vice president, US Operations at Novo Nordisk. ‘Wegovy pill is the next chapter in our decades-long GLP-1 experience.’
Clinical evidence & efficacy
Approval was based on results from the OASIS 4 phase 3 clinical trial, a 71-week, double-blind, randomised, placebo-controlled trial that included 307 adults with obesity or overweight with one or more weight-related comorbidities, without diabetes.
At week 64, participants taking the once-daily 25mg dose along with a reduced calorie diet and exercise achieved an average weight loss of 13.6 percent compared with 2.4 percent for placebo, with a greater effect (16.6 percent) in those fully compliant with therapy versus 2.7 percent with placebo. Around 30 percent of oral participants achieved at least a 20 percent weight loss by week 64.
The weight loss results were found to be comparable to those seen with the weekly injectable version of Wegovy (2.4mg).
Common adverse reactions mirrored those seen with injectable semaglutide and included nausea, diarrhoea and vomiting.
The oral form of Wegovy tablet must be taken first thing in the morning on an empty stomach with only a small amount of water. Patients are advised to swallow it whole and wait at least 30 minutes before eating, drinking or taking any other oral medications.
Implications for obesity care & access
The approval adds to the rapidly expanding landscape of GLP-1-based therapies for obesity, where injectables have dominated clinical practice and significantly shifted treatment paradigms. An effective oral option could broaden patient uptake, enhance adherence in suitable candidates and potentially ease insurance-related access barriers.
‘With more choices, HCPs are better equipped to tailor treatment approaches and support patients who want to gain control of their weight, and this milestone approval underscores exactly that kind of choice,’ said Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham. ‘The availability of Wegovy pill expands the possibilities for weight management with semaglutide, giving healthcare professionals a powerful, efficacious medicine in a new method of delivery, allowing the ability to help meet more patients where they are.’
While longer-term data and real-world evidence will be important to define where Wegovy tablets fit relative to injectables, the FDA’s decision underscores how GLP-1 medicines continue to redefine expectations around medical weight management and reshape how obesity is treated.
